We therefore aimed to investigate treatment response of MDT for bone oligometastatic disease in prostate cancer patients based on the objective parameters SUVmax and PSMA-positive lesion volume on pre- and post-MDT imaging with PSMA-PET/CT. The gene discussed is FOLH1; the disease is prostate carcinoma.